VistaGen, developers of a unique stem-cell based bioassay platform for use in the early identification and elimination of toxicity issues during drug development, plans to use their technology to create a valuable pipeline of drug rescue variants. The company is targeting new drugs that have shown significant potential, but which have been shelved due to heart or liver toxicity issues. VistaGen can effectively rescue those drugs, using their proprietary bioassay technology to help economically solve the toxicity problems, thereby benefitting from all of the research that went into developing the drugs in the first place. The profit potential is enormous, but VistaGen recognizes the critical importance of cultivating strong partnerships to help them realize this strategic goal.
Two of VistaGen’s less publicized but key partnerships and supporters are the National Institutes of Health and the Wisconsin Alumni Research Foundation.
• National Institutes of Health (NIH) – The NIH is the largest source of funding for medical research in the world, made up of 27 institutes and centers. For over a century, NIH scientists have paved the way for important discoveries that improve health and save lives. The medical research agency has created hundreds of thousands of high-quality jobs by funding thousands of scientists in universities and research institutions in every state across America and around the globe. To date, VistaGen has been awarded over $8.5 million from NIH.
• Wisconsin Alumni Research Foundation (WARF) – Since its founding in 1925, the Wisconsin Alumni Research Foundation (WARF) has served the University of Wisconsin-Madison scientific community by patenting the discoveries of UW-Madison researchers and licensing these technologies to leading companies in Wisconsin, the United States, and worldwide. They promote, encourage, and aid scientific investigation and research at the University of Wisconsin-Madison and the Morgridge Institute for Research through helping commercialize the technology arising from that research.
For additional information, visit www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
